1. Home
  2. ANL vs FOR Comparison

ANL vs FOR Comparison

Compare ANL & FOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$10.80

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Logo Forestar Group Inc

FOR

Forestar Group Inc

N/A

Current Price

$22.25

Market Cap

1.1B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ANL
FOR
Founded
2004
2005
Country
Singapore
United States
Employees
N/A
402
Industry
Real Estate
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
1.1B
IPO Year
2022
2007

Fundamental Metrics

Financial Performance
Metric
ANL
FOR
Price
$10.80
$22.25
Analyst Decision
Strong Buy
Buy
Analyst Count
7
3
Target Price
$29.50
★ $34.00
AVG Volume (30 Days)
★ 268.1K
174.4K
Earning Date
08-14-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 1.63
Revenue
N/A
★ $1,662,400,000.00
Revenue This Year
$243.83
N/A
Revenue Next Year
N/A
$8.43
P/E Ratio
★ N/A
$13.58
Revenue Growth
N/A
★ 10.14
52 Week Low
$0.88
$22.04
52 Week High
$17.25
$32.06

Technical Indicators

Market Signals
Indicator
ANL
FOR
Relative Strength Index (RSI) 46.74 33.33
Support Level $8.95 N/A
Resistance Level $11.90 $26.36
Average True Range (ATR) 0.99 0.91
MACD 0.25 -0.24
Stochastic Oscillator 72.55 4.79

Price Performance

Historical Comparison
ANL
FOR

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About FOR Forestar Group Inc

Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.

Share on Social Networks: